25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

OKUR (OnKure Therapeutics, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze OnKure Therapeutics, Inc. together

I guess you are interested in OnKure Therapeutics, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – OnKure Therapeutics, Inc.’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – OnKure Therapeutics, Inc.’s Price Targets

I'm going to help you getting a better view of OnKure Therapeutics, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about OnKure Therapeutics, Inc.

I send you an email if I find something interesting about OnKure Therapeutics, Inc..

1. Quick Overview

1.1. Quick analysis of OnKure Therapeutics, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of OnKure Therapeutics, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.79
Expected worth in 1 year
$20.84
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$15.05
Return On Investment
543.3%

For what price can you sell your share?

Current Price per Share
$2.77
Expected price per share
$0 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of OnKure Therapeutics, Inc. (5 min.)




Live pricePrice per Share (EOD)
$2.77

2.2. Growth of OnKure Therapeutics, Inc. (5 min.)




Is OnKure Therapeutics, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$78.1m-$55.4m$142m164.0%

How much money is OnKure Therapeutics, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$17.5m-$6m-$11.4m-65.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of OnKure Therapeutics, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of OnKure Therapeutics, Inc.?

Welcome investor! OnKure Therapeutics, Inc.'s management wants to use your money to grow the business. In return you get a share of OnKure Therapeutics, Inc..

First you should know what it really means to hold a share of OnKure Therapeutics, Inc.. And how you can make/lose money.

Speculation

The Price per Share of OnKure Therapeutics, Inc. is $2.77. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of OnKure Therapeutics, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in OnKure Therapeutics, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.79. Based on the TTM, the Book Value Change Per Share is $3.76 per quarter. Based on the YOY, the Book Value Change Per Share is $-4.80 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of OnKure Therapeutics, Inc..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.14-41.1%-1.31-47.3%-0.46-16.5%-0.85-30.8%-0.85-30.8%-0.85-30.8%
Usd Book Value Change Per Share-0.97-34.9%3.76135.8%-4.80-173.3%0.6423.2%0.6423.2%0.6423.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.97-34.9%3.76135.8%-4.80-173.3%0.6423.2%0.6423.2%0.6423.2%
Usd Price Per Share2.39-4.25-3.10-3.99-3.99-3.99-
Price to Earnings Ratio-0.52--0.95--0.49--0.94--0.94--0.94-
Price-to-Total Gains Ratio-2.47--0.67--2.47--1.32--1.32--1.32-
Price to Book Ratio0.41-0.62-0.08-0.38-0.38-0.38-
Price-to-Total Gains Ratio-2.47--0.67--2.47--1.32--1.32--1.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.77
Number of shares361
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.760.64
Usd Total Gains Per Share3.760.64
Gains per Quarter (361 shares)1,358.28232.09
Gains per Year (361 shares)5,433.13928.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10543354230928918
201086610856018571846
301629916289027852774
402173321722037133702
502716627155046424630
603259932588055705558
703803238021064996486
804346543454074277414
904889848887083558342
1005433154320092849270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.08.00.011.1%1.08.00.011.1%1.08.00.011.1%1.08.00.011.1%
Book Value Change Per Share2.02.00.050.0%3.06.00.033.3%3.06.00.033.3%3.06.00.033.3%3.06.00.033.3%
Dividend per Share0.00.04.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share2.02.00.050.0%3.06.00.033.3%3.06.00.033.3%3.06.00.033.3%3.06.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of OnKure Therapeutics, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9663.763-126%-4.800+397%0.643-250%0.643-250%0.643-250%
Book Value Per Share--5.7866.468-11%-4.156+172%2.132+171%2.132+171%2.132+171%
Current Ratio--11.13014.186-22%5.013+122%9.716+15%9.716+15%9.716+15%
Debt To Asset Ratio--0.0920.082+12%3.839-98%1.754-95%1.754-95%1.754-95%
Debt To Equity Ratio--0.1010.090+13%0.034+201%0.068+49%0.068+49%0.068+49%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--107756701.200140756834.200-23%-19819580.114+118%77602399.096+39%77602399.096+39%77602399.096+39%
Eps---1.139-1.310+15%-0.456-60%-0.853-25%-0.853-25%-0.853-25%
Ev To Ebitda Ratio---1.7750.519-442%0.219-911%-0.415-77%-0.415-77%-0.415-77%
Free Cash Flow Per Share---0.984-1.145+16%-0.678-31%-0.903-8%-0.903-8%-0.903-8%
Free Cash Flow To Equity Per Share---0.9841.032-195%-0.568-42%0.113-969%0.113-969%0.113-969%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Market Cap35048533.000+8%32286701.20056851834.200-43%41302169.886-22%53346954.652-39%53346954.652-39%53346954.652-39%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio0.479+14%0.4130.615-33%0.078+429%0.382+8%0.382+8%0.382+8%
Pe Ratio-0.608-16%-0.524-0.945+80%-0.493-6%-0.936+79%-0.936+79%-0.936+79%
Price Per Share2.770+14%2.3904.248-44%3.096-23%3.993-40%3.993-40%3.993-40%
Price To Free Cash Flow Ratio-0.704-16%-0.607-0.859+41%-0.405-33%-0.780+28%-0.780+28%-0.780+28%
Price To Total Gains Ratio-2.867-16%-2.473-0.670-73%-2.4650%-1.320-47%-1.320-47%-1.320-47%
Quick Ratio--10.97515.255-28%6.705+64%11.994-9%11.994-9%11.994-9%
Return On Assets---0.179-0.173-3%-0.143-20%-0.147-18%-0.147-18%-0.147-18%
Return On Equity---0.197-0.190-3%-0.042-79%-0.110-44%-0.110-44%-0.110-44%
Total Gains Per Share---0.9663.763-126%-4.800+397%0.643-250%0.643-250%0.643-250%
Usd Book Value--78166000.00086665000.000-10%-55434000.000+171%28605777.778+173%28605777.778+173%28605777.778+173%
Usd Book Value Change Per Share---0.9663.763-126%-4.800+397%0.643-250%0.643-250%0.643-250%
Usd Book Value Per Share--5.7866.468-11%-4.156+172%2.132+171%2.132+171%2.132+171%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--107756701.200140756834.200-23%-19819580.114+118%77602399.096+39%77602399.096+39%77602399.096+39%
Usd Eps---1.139-1.310+15%-0.456-60%-0.853-25%-0.853-25%-0.853-25%
Usd Free Cash Flow---13287000.000-15339500.000+15%-9049000.000-32%-12078555.556-9%-12078555.556-9%-12078555.556-9%
Usd Free Cash Flow Per Share---0.984-1.145+16%-0.678-31%-0.903-8%-0.903-8%-0.903-8%
Usd Free Cash Flow To Equity Per Share---0.9841.032-195%-0.568-42%0.113-969%0.113-969%0.113-969%
Usd Market Cap35048533.000+8%32286701.20056851834.200-43%41302169.886-22%53346954.652-39%53346954.652-39%53346954.652-39%
Usd Price Per Share2.770+14%2.3904.248-44%3.096-23%3.993-40%3.993-40%3.993-40%
Usd Profit---15390000.000-17550250.000+14%-6087000.000-60%-11414666.667-26%-11414666.667-26%-11414666.667-26%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---0.9663.763-126%-4.800+397%0.643-250%0.643-250%0.643-250%
 EOD+5 -3MRQTTM+8 -24YOY+15 -173Y+8 -245Y+8 -2410Y+8 -24

3.3 Fundamental Score

Let's check the fundamental score of OnKure Therapeutics, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.608
Price to Book Ratio (EOD)Between0-10.479
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.975
Current Ratio (MRQ)Greater than111.130
Debt to Asset Ratio (MRQ)Less than10.092
Debt to Equity Ratio (MRQ)Less than10.101
Return on Equity (MRQ)Greater than0.15-0.197
Return on Assets (MRQ)Greater than0.05-0.179
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of OnKure Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.710
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

Fundamental data was last updated by Penke on 2025-08-16 23:52:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ OnKure Therapeutics, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of OnKure Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--95.1%+95.1%
TTM--142.2%+142.2%
YOY--205.6%+205.6%
3Y--257.3%+257.3%
5Y--343.4%+343.4%
10Y--503.2%+503.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ OnKure Therapeutics, Inc. is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • -17.9% Return on Assets means thatΒ OnKure Therapeutics, Inc. generatedΒ $-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of OnKure Therapeutics, Inc.:

  • The MRQ is -17.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.9%TTM-17.3%-0.6%
TTM-17.3%YOY-14.3%-3.0%
TTM-17.3%5Y-14.7%-2.6%
5Y-14.7%10Y-14.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.9%-11.6%-6.3%
TTM-17.3%-11.4%-5.9%
YOY-14.3%-11.3%-3.0%
3Y-14.7%-11.6%-3.1%
5Y-14.7%-11.8%-2.9%
10Y-14.7%-13.6%-1.1%
4.3.1.3. Return on Equity

Shows how efficient OnKure Therapeutics, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • -19.7% Return on Equity means OnKure Therapeutics, Inc. generated $-0.20Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of OnKure Therapeutics, Inc.:

  • The MRQ is -19.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.7%TTM-19.0%-0.7%
TTM-19.0%YOY-4.2%-14.9%
TTM-19.0%5Y-11.0%-8.0%
5Y-11.0%10Y-11.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.7%-13.3%-6.4%
TTM-19.0%-14.5%-4.5%
YOY-4.2%-14.5%+10.3%
3Y-11.0%-16.5%+5.5%
5Y-11.0%-17.1%+6.1%
10Y-11.0%-19.2%+8.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of OnKure Therapeutics, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient OnKure Therapeutics, Inc. is operatingΒ .

  • Measures how much profit OnKure Therapeutics, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of OnKure Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--190.4%+190.4%
TTM--234.1%+234.1%
YOY--212.3%+212.3%
3Y--240.5%+240.5%
5Y--348.6%+348.6%
10Y--488.3%+488.3%
4.3.2.2. Operating Ratio

Measures how efficient OnKure Therapeutics, Inc. is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of OnKure Therapeutics, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.026-2.026
TTM-2.666-2.666
YOY-3.011-3.011
3Y-3.512-3.512
5Y-4.642-4.642
10Y-6.651-6.651
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of OnKure Therapeutics, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if OnKure Therapeutics, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 11.13Β means the company has $11.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of OnKure Therapeutics, Inc.:

  • The MRQ is 11.130. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.186. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.130TTM14.186-3.056
TTM14.186YOY5.013+9.172
TTM14.1865Y9.716+4.469
5Y9.71610Y9.7160.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1303.543+7.587
TTM14.1863.775+10.411
YOY5.0134.140+0.873
3Y9.7164.680+5.036
5Y9.7165.742+3.974
10Y9.7166.175+3.541
4.4.3.2. Quick Ratio

Measures if OnKure Therapeutics, Inc. is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Quick Ratio of 10.97Β means the company can pay off $10.97 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of OnKure Therapeutics, Inc.:

  • The MRQ is 10.975. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.255. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.975TTM15.255-4.281
TTM15.255YOY6.705+8.550
TTM15.2555Y11.994+3.261
5Y11.99410Y11.9940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.9753.128+7.847
TTM15.2553.433+11.822
YOY6.7053.928+2.777
3Y11.9944.516+7.478
5Y11.9945.876+6.118
10Y11.9946.523+5.471
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of OnKure Therapeutics, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of OnKure Therapeutics, Inc.Β assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ OnKure Therapeutics, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09Β means that OnKure Therapeutics, Inc. assets areΒ financed with 9.2% credit (debt) and the remaining percentage (100% - 9.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of OnKure Therapeutics, Inc.:

  • The MRQ is 0.092. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.082. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.082+0.010
TTM0.082YOY3.839-3.757
TTM0.0825Y1.754-1.672
5Y1.75410Y1.7540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.342-0.250
TTM0.0820.356-0.274
YOY3.8390.332+3.507
3Y1.7540.340+1.414
5Y1.7540.350+1.404
10Y1.7540.378+1.376
4.5.4.2. Debt to Equity Ratio

Measures ifΒ OnKure Therapeutics, Inc. is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 10.1% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of OnKure Therapeutics, Inc.:

  • The MRQ is 0.101. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.090. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.101TTM0.090+0.011
TTM0.090YOY0.034+0.056
TTM0.0905Y0.068+0.022
5Y0.06810Y0.0680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1010.390-0.289
TTM0.0900.440-0.350
YOY0.0340.419-0.385
3Y0.0680.455-0.387
5Y0.0680.464-0.396
10Y0.0680.511-0.443
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings OnKure Therapeutics, Inc. generates.

  • Above 15 is considered overpriced butΒ always compareΒ OnKure Therapeutics, Inc. to theΒ Biotechnology industry mean.
  • A PE ratio of -0.52 means the investor is paying $-0.52Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of OnKure Therapeutics, Inc.:

  • The EOD is -0.608. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.524. Based on the earnings, the company is expensive. -2
  • The TTM is -0.945. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.608MRQ-0.524-0.083
MRQ-0.524TTM-0.945+0.421
TTM-0.945YOY-0.493-0.452
TTM-0.9455Y-0.936-0.009
5Y-0.93610Y-0.9360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.608-2.518+1.910
MRQ-0.524-2.092+1.568
TTM-0.945-2.752+1.807
YOY-0.493-3.911+3.418
3Y-0.936-3.875+2.939
5Y-0.936-6.363+5.427
10Y-0.936-6.876+5.940
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of OnKure Therapeutics, Inc.:

  • The EOD is -0.704. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.607. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.859. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.704MRQ-0.607-0.097
MRQ-0.607TTM-0.859+0.251
TTM-0.859YOY-0.405-0.454
TTM-0.8595Y-0.780-0.079
5Y-0.78010Y-0.7800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.704-3.678+2.974
MRQ-0.607-2.839+2.232
TTM-0.859-3.941+3.082
YOY-0.405-4.426+4.021
3Y-0.780-5.256+4.476
5Y-0.780-8.609+7.829
10Y-0.780-9.357+8.577
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ OnKure Therapeutics, Inc. is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.41 means the investor is paying $0.41Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of OnKure Therapeutics, Inc.:

  • The EOD is 0.479. Based on the equity, the company is cheap. +2
  • The MRQ is 0.413. Based on the equity, the company is cheap. +2
  • The TTM is 0.615. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.479MRQ0.413+0.066
MRQ0.413TTM0.615-0.202
TTM0.615YOY0.078+0.537
TTM0.6155Y0.382+0.234
5Y0.38210Y0.3820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4792.321-1.842
MRQ0.4131.909-1.496
TTM0.6152.210-1.595
YOY0.0782.525-2.447
3Y0.3822.530-2.148
5Y0.3823.728-3.346
10Y0.3824.400-4.018
4.6.2. Total Gains per Share

2.4. Latest News of OnKure Therapeutics, Inc.

Does OnKure Therapeutics, Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from OnKure Therapeutics, Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-08-12
23:25
OnKure Therapeutics Inc-A (NASDAQ:OKUR) Reports Q2 2025 Earnings Beat with Narrower-Than-Expected LossRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of OnKure Therapeutics, Inc..

4.8.3. Insider Transactions

Insiders are holding 1.451% of the shares of OnKure Therapeutics, Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-23Jason A LeveroneSELL3032.38
2025-06-23Nicholas A SaccomanoSELL882.38
2025-05-15Cormorant Asset Management, LpSELL18134391.85
2025-05-12Cormorant Asset Management, LpSELL243001.99
2025-04-07Jason A LeveroneSELL18442.67
2025-04-07Nicholas A SaccomanoSELL5162.67
2025-04-04Jason A LeveroneSELL12783.33
2025-04-04Nicholas A SaccomanoSELL3583.33
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets86,070
Total Liabilities7,904
Total Stockholder Equity78,166
 As reported
Total Liabilities 7,904
Total Stockholder Equity+ 78,166
Total Assets = 86,070

Assets

Total Assets86,070
Total Current Assets84,552
Long-term Assets1,518
Total Current Assets
Cash And Cash Equivalents 83,374
Other Current Assets 1,178
Total Current Assets  (as reported)84,552
Total Current Assets  (calculated)84,552
+/-0
Long-term Assets
Property Plant Equipment 1,402
Long-term Assets Other 116
Long-term Assets  (as reported)1,518
Long-term Assets  (calculated)1,518
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,597
Long-term Liabilities307
Total Stockholder Equity78,166
Total Current Liabilities
Short-term Debt 556
Accounts payable 2,381
Other Current Liabilities 4,660
Total Current Liabilities  (as reported)7,597
Total Current Liabilities  (calculated)7,597
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt267
Long-term Liabilities Other 40
Long-term Liabilities  (as reported)307
Long-term Liabilities  (calculated)307
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -186,039
Other Stockholders Equity 264,204
Total Stockholder Equity (as reported)78,166
Total Stockholder Equity (calculated)78,166
+/-0
Other
Capital Stock1
Cash and Short Term Investments 83,374
Common Stock Shares Outstanding 13,509
Liabilities and Stockholders Equity 86,070
Net Debt -82,551
Net Invested Capital 78,166
Net Working Capital 76,955
Property Plant and Equipment Gross 2,756
Short Long Term Debt Total 823



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
> Total Assets 
0
148,039
130,388
35,734
24,527
25,473
77,645
114,907
99,882
86,070
86,07099,882114,90777,64525,47324,52735,734130,388148,0390
   > Total Current Assets 
0
146,320
128,772
33,766
22,708
23,796
76,999
113,003
98,172
84,552
84,55298,172113,00376,99923,79622,70833,766128,772146,3200
       Cash And Cash Equivalents 
0
9,081
11,737
29,876
19,248
18,633
60,689
110,761
96,661
83,374
83,37496,661110,76160,68918,63319,24829,87611,7379,0810
       Short-term Investments 
0
133,596
113,877
0
0
0
15,979
0
0
0
00015,979000113,877133,5960
       Net Receivables 
0
0
0
0
0
2,045
0
0
0
0
00002,04500000
       Other Current Assets 
0
3,643
3,158
3,890
3,460
3,118
331
2,242
1,511
1,178
1,1781,5112,2423313,1183,4603,8903,1583,6430
   > Long-term Assets 
0
1,719
1,616
1,968
1,819
1,677
646
1,904
1,710
1,518
1,5181,7101,9046461,6771,8191,9681,6161,7190
       Property Plant Equipment 
0
1,640
1,535
1,910
1,768
1,628
499
1,795
1,601
1,402
1,4021,6011,7954991,6281,7681,9101,5351,6400
> Total Liabilities 
0
15,511
15,444
137,576
135,788
149,050
3,627
11,079
9,234
7,904
7,9049,23411,0793,627149,050135,788137,57615,44415,5110
   > Total Current Liabilities 
0
13,738
13,563
7,285
5,551
12,984
3,248
10,530
8,785
7,597
7,5978,78510,5303,24812,9845,5517,28513,56313,7380
       Short-term Debt 
0
318
325
208
212
216
572
1,072
1,092
556
5561,0921,0725722162122083253180
       Accounts payable 
0
1,828
2,473
3,417
3,623
8,261
237
2,968
2,344
2,381
2,3812,3442,9682378,2613,6233,4172,4731,8280
       Other Current Liabilities 
0
11,592
10,765
3,660
1,716
4,507
2,439
6,490
5,349
4,660
4,6605,3496,4902,4394,5071,7163,66010,76511,5920
   > Long-term Liabilities 
0
1,773
1,881
130,291
130,237
136,066
379
549
449
307
307449549379136,066130,237130,2911,8811,7730
> Total Stockholder Equity
0
132,528
114,944
-101,842
-111,261
-123,577
74,018
103,828
90,648
78,166
78,16690,648103,82874,018-123,577-111,261-101,842114,944132,5280
   Common Stock
0
3
3
0
1
1
0
1
1
1
1110110330
   Retained Earnings Total Equity0000000000
   Accumulated Other Comprehensive Income 
0
-31
-21
0
0
0
2
0
0
0
0002000-21-310
   Capital Surplus 0000000000
   Treasury Stock0000000000
   Other Stockholders Equity 
0
303,877
305,479
209
325
2,148
309,969
258,551
261,296
264,204
264,204261,296258,551309,9692,148325209305,479303,8770



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-662
Gross Profit-662-662
 
Operating Income (+$)
Gross Profit-662
Operating Expense-54,386
Operating Income-54,386-55,048
 
Operating Expense (+$)
Research Development43,795
Selling General Administrative10,591
Selling And Marketing Expenses0
Operating Expense54,38654,386
 
Net Interest Income (+$)
Interest Income2,013
Interest Expense-300
Other Finance Cost-0
Net Interest Income1,713
 
Pretax Income (+$)
Operating Income-54,386
Net Interest Income1,713
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-52,673-56,099
EBIT - interestExpense = -52,673
-52,673
-52,373
Interest Expense300
Earnings Before Interest and Taxes (EBIT)-52,373-52,373
Earnings Before Interest and Taxes (EBITDA)-51,711
 
After tax Income (+$)
Income Before Tax-52,673
Tax Provision-0
Net Income From Continuing Ops-52,673-52,673
Net Income-52,673
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses54,386
Total Other Income/Expenses Net1,713-1,713
 

Technical Analysis of OnKure Therapeutics, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of OnKure Therapeutics, Inc.. The general trend of OnKure Therapeutics, Inc. is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine OnKure Therapeutics, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. OnKure Therapeutics, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of OnKure Therapeutics, Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.
OnKure Therapeutics, Inc. Daily Support & Resistance ChartOnKure Therapeutics, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of OnKure Therapeutics, Inc.. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

OnKure Therapeutics, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartOnKure Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of OnKure Therapeutics, Inc.. The current adx is .

OnKure Therapeutics, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Relative Strength Index (RSI) ChartOnKure Therapeutics, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Stochastic Oscillator ChartOnKure Therapeutics, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Commodity Channel Index (CCI) ChartOnKure Therapeutics, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) ChartOnKure Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Williams %R ChartOnKure Therapeutics, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Average True Range (ATR) ChartOnKure Therapeutics, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily On-Balance Volume (OBV) ChartOnKure Therapeutics, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc. Daily Money Flow Index (MFI) ChartOnKure Therapeutics, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for OnKure Therapeutics, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

OnKure Therapeutics, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of OnKure Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.710
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of OnKure Therapeutics, Inc. with someone you think should read this too:
  • Are you bullish or bearish on OnKure Therapeutics, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about OnKure Therapeutics, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about OnKure Therapeutics, Inc.

I send you an email if I find something interesting about OnKure Therapeutics, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about OnKure Therapeutics, Inc..

Receive notifications about OnKure Therapeutics, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.